Clinical Research Directory
Browse clinical research sites, groups, and studies.
Antisecretory Factor Glioblastoma Phase 2
Sponsor: Peter Siesjö
Summary
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
Official title: Antisecretory Factor During Concomitant and Adjuvant Therapy of Primary Glioblastoma, a Randomised, Prospective and Double Blinded Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2024-01-15
Completion Date
2027-12-01
Last Updated
2026-01-09
Healthy Volunteers
No
Conditions
Interventions
Salovum
Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
Placebo egg yolk powder
Egg yolk powder derived from hen fed with normal feed.
Locations (1)
Skåne University Hospital
Lund, Sweden